Canada’s federal health regulator has approved Jazz Pharmaceuticals Canada’s cannabinoid-based medicine Epidiolex as a supplementary therapy for certain rare and severe forms of epilepsy, allowing the company to bring to market a clinically tested drug with global sales that dwarf those of the nation’s entire medical cannabis industry.
Epidiolex is the top-selling clinically proven cannabinoid-based medicine in the world, with global sales through the first nine months of Jazz’s fiscal year totaling approximately $604.8 million (823 million Canadian dollars).
ADVERTISEMENT
By comparison, in calendar year 2022, Canadian patients purchased CA$410 million dollars of cannabis products for medical use, 7.4% lower than in 2021, according to Statistics Canada.
Health Canada’s approval of Epidiolex makes Canada the 36th country to approve the cannabis-based drug, a prescription medicine that is administered as an oral solution.
Some others include the United States, the European Union and South Korea.
Epidiolex is produced
Read full article on Marijuana Business Daily
